A U.S. District Judge has granted class-action status to former Wyeth investors who accused the...

|By:, SA News Editor

A U.S. District Judge has granted class-action status to former Wyeth investors who accused the Pfizer (PFE -0.1%) unit of misleading them about risks associated with its antidepressant drug Pristiq. The FDA rejected the drug in July, 2007 over potential serious heart and liver problems associated with its use. A Pfizer spokesperson says the company will continue to defend itself vigorously.